Barclays
TNGX icon

Barclays’s Tango Therapeutics TNGX Stock Holding History

Barclays’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68M Buy
53,762
+32,092
+148% +$793K ﹤0.01% 2445
2026
Q1 		$453K Sell
21,670
-346,517
-94% -$4.82M ﹤0.01% 3244
2025
Q4 		$3.26M Buy
368,187
+2,507
+0.7% +$21.6K ﹤0.01% 2569
2025
Q3 		$3.07M Buy
365,680
+227,030
+164% +$1.54M ﹤0.01% 2544
2025
Q2 		$710K Buy
138,650
+75,618
+120% +$187K ﹤0.01% 3552
2025
Q1 		$86.4K Sell
63,032
-36,742
-37% -$90.2K ﹤0.01% 4459
2024
Q4 		$308K Sell
99,774
-26,507
-21% -$123K ﹤0.01% 4106
2024
Q3 		$972K Buy
126,281
+55,470
+78% +$529K ﹤0.01% 3381
2024
Q2 		$608K Sell
70,811
-112,675
-61% -$871K ﹤0.01% 2923
2024
Q1 		$1.46M Sell
183,486
-18,413
-9% -$197K ﹤0.01% 2827
2023
Q4 		$2M Buy
201,899
+114,017
+130% +$990K ﹤0.01% 2918
2023
Q3 		$990K Buy
87,882
+31,618
+56% +$193K ﹤0.01% 2342
2023
Q2 		$187K Sell
56,264
-3,265
-5% -$11.7K ﹤0.01% 3278
2023
Q1 		$235K Sell
59,529
-22,993
-28% -$133K ﹤0.01% 3695
2022
Q4 		$598K Sell
82,522
-37,193
-31% -$262K ﹤0.01% 3197
2022
Q3 		$433K Sell
119,715
-19,121
-14% -$81.7K ﹤0.01% 2789
2022
Q2 		$629K Buy
138,836
+15,927
+13% +$96.4K ﹤0.01% 2692
2022
Q1 		$932K Buy
+122,909
New +$1.07M ﹤0.01% 2469

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Barclays's TNGX Position: Q2 2026 in Review

Barclays increased its Tango Therapeutics (TNGX) stake by 148% in Q2 2026, buying an estimated $793K and bringing the position to 53,762 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2445.

Barclays first reported a position in TNGX in Q1 2022 and has held it in 18 quarters since. The position peaked at $3.26M in Q4 2025. 247 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Barclays held 53,762 shares of Tango Therapeutics worth $1.68M as of Q2 2026.
  • Barclays bought 32,092 Tango Therapeutics shares in Q2 2026, an estimated $793K.
  • Tango Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2445 holding.
  • Barclays first reported a position in Tango Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Tango Therapeutics position peaked at $3.26M in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.